Usefulness of Proteinuria as a Prognostic Marker of Mortality and Cardiovascular Events Among Patients Undergoing Percutaneous Coronary Intervention (Data from the Evaluation of Oral Xemilofiban in Controlling Thrombotic Events [EXCITE] Trial)

MLA

Joachim H. Ix, et al. “Usefulness of Proteinuria as a Prognostic Marker of Mortality and Cardiovascular Events Among Patients Undergoing Percutaneous Coronary Intervention (Data from the Evaluation of Oral Xemilofiban in Controlling Thrombotic Events [EXCITE] Trial).” The American Journal of Cardiology, vol. 102, Nov. 2008, pp. 1151–55. EBSCOhost, https://doi.org/10.1016/j.amjcard.2008.06.035.

APA

Joachim H. Ix, Pedro A. Lemos, Paul S. Teirstein, Patrick W. Serruys, William Wijns, Mimi Guarneri, Nestor Mercado, Simon R. Dixon, Jasper J. Brugts, William W. O’Neill, Michael G. Shlipak, Bernard J. Gersh, & Eric Boersma. (2008). Usefulness of Proteinuria as a Prognostic Marker of Mortality and Cardiovascular Events Among Patients Undergoing Percutaneous Coronary Intervention (Data from the Evaluation of Oral Xemilofiban in Controlling Thrombotic Events [EXCITE] Trial). The American Journal of Cardiology, 102, 1151–1155. https://doi.org/10.1016/j.amjcard.2008.06.035

Chicago

Joachim H. Ix, Pedro A. Lemos, Paul S. Teirstein, Patrick W. Serruys, William Wijns, Mimi Guarneri, Nestor Mercado, et al. 2008. “Usefulness of Proteinuria as a Prognostic Marker of Mortality and Cardiovascular Events Among Patients Undergoing Percutaneous Coronary Intervention (Data from the Evaluation of Oral Xemilofiban in Controlling Thrombotic Events [EXCITE] Trial).” The American Journal of Cardiology 102 (November): 1151–55. doi:10.1016/j.amjcard.2008.06.035.